Deutsche Bank maintains its Buy rating on Medicis Pharmaceutical MRX and has increased the price target from $36 to $40, “reflecting recent multiple expansions in the sector”.
MRX closed yesterday at $34.27.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Analyst ColorAnalyst RatingsDeutsche BankHealth CareMedicis Pharmaceutical Corp.Pharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
